Focus Partners Advisor Solutions LLC Decreases Stake in Eli Lilly and Company $LLY

Key Points

• Focus Partners Advisor Solutions LLC reduced its stake in Eli Lilly by 9.9% in Q2, selling 1,540 shares, leaving them with a value of $10,889,000 in holdings.
• Several hedge funds are adjusting their positions, with Brighton Jones LLC increasing its stake by 22.0% in Q4, thus highlighting a mixed sentiment among institutional investors.
• Eli Lilly reported $6.31 earnings per share in its latest quarter, exceeding expectations and marking a 37.6% revenue increase compared to the previous year.

Focus Partners Advisor Solutions LLC trimmed its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 9.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,962 shares of the company's stock after selling 1,540 shares during the period. Focus Partners Advisor Solutions LLC's holdings in Eli Lilly and Company were worth $10,889,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after buying an additional 40 shares in the last quarter. Covestor Ltd raised its stake in Eli Lilly and Company by 24.9% in the first quarter. Covestor Ltd now owns 426 shares of the company's stock valued at $352,000 after buying an additional 85 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Eli Lilly and Company by 25.8% during the 1st quarter. GAMMA Investing LLC now owns 18,000 shares of the company's stock worth $14,866,000 after buying an additional 3,696 shares during the last quarter. Finally, Alpine Bank Wealth Management acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth about $903,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of the company's stock in a transaction on Friday, August 8th. The shares were bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the transaction, the director owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares of the company's stock, valued at $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $825.86 on Friday. The firm's fifty day simple moving average is $768.01 and its 200-day simple moving average is $768.14. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The stock has a market capitalization of $781.65 billion, a price-to-earnings ratio of 53.98, a PEG ratio of 1.18 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the prior year, the business earned $3.92 EPS. Eli Lilly and Company's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Analysts Set New Price Targets

LLY has been the subject of several recent analyst reports. Berenberg Bank restated a "hold" rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Weiss Ratings reissued a "hold (c+)" rating on shares of Eli Lilly and Company in a report on Friday. Morgan Stanley reduced their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a research report on Friday, October 3rd. Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Finally, Guggenheim reissued a "buy" rating and issued a $948.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $938.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.